Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 4, 2017

Aptar Pharma to Exhibit and Present at CPhI Worldwide 2017

Aptar Pharma will be a main exhibitor at CPhI Worldwide 2017 and will deliver three briefings on company drug-delivery developments.

On Oct. 4, 2017, Aptar Pharma, a drug delivery systems provider, announced that it will be a main exhibitor at CPhI Worldwide 2017, which takes place in Frankfurt, Germany from October 24–26, 2017. Their exhibition will include information on their offers in drug delivery systems, components, and services covering a range of delivery routes.

The company booth, located at stand No. 42F10, Hall 4.2, will feature an area showcasing seven healthcare technology megatrends, including a connectivity hub, which will be dedicated to the field of connected healthcare solutions. Additionally, the company will present three pharma insight briefings that will highlight its latest developments in the following drug delivery system areas.

Respiratory Solutions for Expanding Product Portfolio

Guenter Nadler, director business development at Aptar Pharma, will discuss innovative respiratory solutions on the first day of the event. Attendees will learn more about how the company’s nasal spray and Bag on Valve systems meet today’s requirements for compliant patient treatment of upper respiratory tract diseases. Nadler’s briefing will take place on Tuesday, Oct. 24, 2017 at 10:30 at the Innopack Zone, G1A3.

Driving Patient Outcomes with Connectivity

Sai Shankar, director business development for connected devices at Aptar Pharma, will present on connected technology solutions for the treatment of respiratory diseases, including asthma and chronic obstructive pulmonary disease. The topics of the talk include study findings on the company’s integrated connected pressurized metered-dose inhaler, and its connected health devices portfolio that support respiratory treatment for patients. Shankar’s briefing will take place on Tuesday, Oct. 24, 2017 at 15:50 at the Innopack Zone, G1A3.  

Setting New Standards for Coated Stoppers

Arnaud Fournier, senior business project manager for injectables at Aptar Pharma, will introduce PremiumCoat, a coated stopper which represents a change in the provision of elastomeric stoppers with reduction in particulates, as well as the company’s injectables portfolio. Fournier’s briefing will take place on Wednesday, Oct. 25 at 10:30 at the Innopack Zone, G1A3.

Source: Aptar Pharma


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.